We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Craig
McAllister
c.j.mcallister@bham.ac.uk
Craig
McAllister
c.j.mcallister@bham.ac.uk
Aliya
Warden
aliyawarden@gmail.com
Extrapyramidal and movement disorders
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Aside from typical movement symptoms, individuals with Parkinson’s disease also have an increased risk of developing impulse control disorders, such as pathological gambling, hyper-aggression and binge eating.
Dopamine medications remain the best method to treat motor symptoms, such as tremor, but are the greatest risk factor for impulse control disorders in Parkinson’s. These behaviours can present severe negative implications for people affected by Parkinson’s and their families, yet there is currently no reliable way to identify individuals who are at risk of developing an impulse control disorder.
The purpose of this study is to examine new measures at the level of the muscle and brain to reveal sensitive markers of impaired inhibitory control that might indicate a higher risk of developing impulse control disorders. Participants’ performance on a cognitive-motor task will be investigated. During this task, several measures of muscle and brain activity will be taken, involving non-invasive recording of brain electrical activity, muscle recording, and non-invasive brain stimulation techniques.
To isolate the effects of the disease pathology from the effects of dopamine medication on impulse control, we will recruit 3 study groups:
- Healthy older adults (control group)
- Individuals with PD who are not yet taking medication
- Individuals with PD who are taking ropinirole as a part of their medications
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cross-sectional;
You can take part if:
You may not be able to take part if:
Principal exclusion criteria: • An inability to provide informed consent (characterised as a score of < 24 on the Montreal Cognitive Assessment) • An inability to comprehend the task instructions (provided in spoken and written English) • Contraindications to TMS (assessed via the TMS safety questionnaire)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Aliya
Warden
aliyawarden@gmail.com
Craig
McAllister
c.j.mcallister@bham.ac.uk
Craig
McAllister
c.j.mcallister@bham.ac.uk
The study is sponsored by University of Birmingham and funded by THE HUMANE RESEARCH TRUST .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 58972
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
